ADAs to alemtuzumab
Research type
Research Study
Full title
Impact of anti-drug antibodies on the safety and clinical efficacy of alemtuzumab in multiple sclerosis
IRAS ID
304993
Contact name
Sharmilee Gnanapavan
Contact email
Sponsor organisation
Barts Health NHS Trust
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Antibody based therapies such as alemtuzumab have been shown to be highly efficacious in lowering disease activity in multiple sclerosis. However, their repeated administration can elicit an undesirable anti-drug response that negate its activity and may eventually lead to adverse reactions in those receiving the drug. We currently don’t know the level of ADA response in alemtuzumab and the factors that influence it. This study will be looking at this across a two year period as blood tests and finger prick blood spots over the alemtuzumab treatment, to study this in greater detail.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
21/NE/0234
Date of REC Opinion
21 Dec 2021
REC opinion
Unfavourable Opinion